Regeneron tops quarterly estimates on eczema drug strength, shares rise

• Dupixent global net sales surged 38% to approximately $6 billion, significantly exceeding analyst estimates of $5.34 billion
• High-dose Eylea (8-mg version) U.S. sales jumped 52% to $596 million, though the lower-dose version faced competitive pressures as patients transitioned to the higher dose
• Regeneron fully repaid its outstanding Sanofi Development Balance, which analysts expect will improve margins and strengthen second-half financial performance

Summary: Regeneron Beats Q2 Estimates on Strong Drug Performance

Key Financial Results:

Regeneron Pharmaceuticals exceeded Wall Street expectations for Q2, with quarterly revenue rising 17% to $4.29 billion, surpassing estimates of $3.82 billion. Adjusted non-GAAP profit reached $14.29 per share. The company's shares rose following the announcement.

Product Performance:

The primary growth driver was Dupixent, Regeneron's eczema drug developed with partner Sanofi. Global net sales surged 38% to approximately $6 billion, significantly beating analyst estimates of $5.34 billion (LSEG data).

The high-dose version (8-mg) of eye drug Eylea demonstrated strong momentum, with U.S. sales jumping 52% to $596 million, driven by higher demand and sales volumes despite lower pricing. However, the lower-dose version faced competitive pressures and patient migration to the higher-dose formulation.

Corporate Developments:

Regeneron announced full repayment of the Sanofi Development Balance, settling outstanding amounts owed to Sanofi for prior collaboration development activities. This debt elimination is expected to improve margins going forward.

Market Implications:

RBC Capital Markets analyst Brian Abrahams noted the "commercial outperformance" should boost investor sentiment, with improved margins from the Sanofi repayment expected to strengthen second-half results. The strong performance in Dupixent reinforces Regeneron's position in the growing eczema treatment market, while the successful transition to high-dose Eylea demonstrates effective product portfolio management.

The Tarrytown, New York-based drugmaker's results reflect robust demand across its key franchises and improved financial positioning following debt settlement.